Toutes les études
Actif, mais pas en recrutementPHASE1, PHASE2INTERVENTIONNEL

Phase 1/2 Clinical Trial of LY3884963 in Patients With Frontotemporal Dementia With Progranulin Mutations (FTD-GRN)

This research study is looking at a new medicine called LY3884963 for a type of Frontotemporal Dementia (FTD) linked to a faulty progranulin gene. It's an early-stage study, meaning it's one of the first times this medicine is being given to people. Researchers want to find out if it's safe to use and how well it's tolerated. They will also check if the medicine changes the levels of a protein called progranulin in the body, which might be important for FTD. The study will continue for five years, with closer monitoring in the first year, and longer-term follow-up to see how people respond over time.

En un coup d'œil

Statut
Actif, mais pas en recrutement
Phase
PHASE1, PHASE2
Sponsor
Prevail Therapeutics
Objectif d'inscription
35
Démarrer
09 Nov 2020
Achèvement estimé
30 Nov 2029

De quoi parle cette étude ?

Frontotemporal Dementia (FTD) is a condition that affects certain parts of the brain, leading to changes in a person's behavior, language, or movement. Sometimes, FTD is caused by a change, or mutation, in a specific gene called progranulin (GRN). This study is for people with this particular type of FTD.

The main goal of this study is to test a new medicine, LY3884963, which is designed to help with FTD caused by the progranulin gene mutation. Because it's a new medicine being tested in humans for the first time, the study is divided into two phases. In the first phase, researchers will give small, increasing doses of the medicine to a few people to make sure it's safe and to see how the body reacts to it. In the second phase, more people will receive the medicine to gather more information on its safety and potential effects.

Researchers will be looking closely at how safe the medicine is and if there are any side effects. They'll also measure the levels of the progranulin protein in the body, as this is thought to be important for the condition. The overall study will last for five years, with detailed check-ups in the first year, followed by four years of monitoring for safety and any changes in the condition.

Points clés

  • Tests a new medicine (LY3884963) for a specific type of FTD.
  • Aims to check safety and if it affects progranulin protein levels.
  • Participation involves regular check-ups for 5 years.
  • Medicine is given directly into the fluid around the brain and spinal cord.
  • Eligibility requires a confirmed progranulin gene mutation and specific age/health criteria.

Qui peut être éligible ?

To join this study, you need to be a man or a woman between 30 and 85 years old. You should have been diagnosed with Frontotemporal Dementia (FTD) that's causing noticeable changes in your behavior, thinking, movement, or language, as assessed by a doctor. Importantly, your FTD must be caused by a specific change in your progranulin (GRN) gene, which will be confirmed by genetic testing.

There are also some general health requirements, such as weighing between 40 kg and 110 kg, and having a body mass index (BMI) between 18 and 34. Any other medicines you're taking should have been stable for at least 8 weeks before starting the study. You'll also need to have up-to-date cancer screenings and a negative test for tuberculosis.

For women, if you're able to have children, you must use highly effective contraception throughout the study. If you're no longer able to have children (e.g., after menopause or certain surgeries), you'll need to meet specific criteria. All participants, or their legal representative, must be able to understand the study and agree to take part by signing a consent form.

Cet étude pourrait-elle vous convenir ?

Répondez à ces questions rapides pour voir si vous êtes éligible. Ceci est un guide uniquement — l'équipe de recherche prend la décision finale.

  1. Are you between 30 and 85 years old?
  2. Do you have Frontotemporal Dementia that's causing symptoms?
  3. Has your doctor confirmed your FTD is due to a progranulin (GRN) gene change?
  4. Are you able to maintain a stable weight within the study's limits?
  5. Are you (or your legal guardian) able to understand and agree to the study details?
Répondez à chaque question pour voir votre résultat.

En quoi consiste la participation ?

If you join this study, you will receive the new medicine, LY3884963, directly into the fluid around your brain and spinal cord (a procedure called intra-cisternal administration). The medicine will be given in increasing doses, starting with a low dose and potentially moving to a medium dose, depending on which group you are in. You might also receive other medicines like methylprednisolone, sirolimus, or prednisone, if needed, as decided by the study doctors.

For the first year, you will have regular visits for check-ups. During these visits, the study team will monitor your safety, using blood tests, scans, and other assessments. They will also look at how your body handles the medicine, called tolerability, and measure levels of important proteins (biomarkers) to see if the medicine is having an effect. They will also assess your FTD symptoms to see if there are any changes.

After the first year, you will continue to be part of the study for another four years. During this longer follow-up period, there will be fewer visits, but the team will still monitor your safety and keep track of certain biomarkers and how your FTD symptoms are progressing. The total length of your participation in this study will be five years.

Risques et avantages potentiels

Taking part in this study means you could be among the first people to receive this new medicine, which might potentially help with your Frontotemporal Dementia caused by a specific gene change. However, as with any new medicine, there are potential risks, including side effects that may not be fully known yet. The medicine will be given directly into the fluid surrounding your brain, which is a procedure that carries its own risks, such as infection or headache, though every care will be taken to minimise these. You will be closely monitored for any problems. Throughout the study, you have the right to withdraw at any time, for any reason, without it affecting your medical care.

Locations (12)

  • k2 Medical Research-Maitland
    Code postal vérifié
    Maitland, United States
  • PPD Phase 1 Clinic, 100 West Gore Street, Suite 202
    Code postal vérifié
    Orlando, United States
  • Lahey Hospital & Medical Center, 41 Burlington Mall Road
    Code postal vérifié
    Burlington, United States
  • Hospital of the University of Pennsylvania, 3 West Gates Building, 3400 Spruce Street
    Code postal vérifié
    Philadelphie, États-Unis
  • Royal Prince Alfred Hospital, Brain & Mind Research Institute, 94 Mallet Street
    Code postal vérifié
    Camperdown, Australia
  • UZ Leuven, Neurologie Herestraat 49
    Code postal vérifié
    Leuven, Belgium
  • AP-HM Hôpital de La Timone
    Code postal vérifié
    Saint-Pierre, France
  • Centre Mémoire de Ressources
    Code postal vérifié
    Lille, France
  • Le Ber, Institut du Cerveau et de la Moelle Epinière
    Code postal vérifié
    Paris, France
  • Hospital Clinic de Barcelona, Villaroel 170 Servicio de Neurología
    Code postal vérifié
    Barcelona, Spain
  • Hospital Universitario de Donostia, Servicio De Neurologia, Consultas Externas Neurologia, San Sebastian, Guipúzcoa
    Code postal vérifié
    Donostia / San Sebastian, Spain
  • University College London,Queen Square, Dementia Research Building, London,
    Code postal vérifié
    Londres, Royaume-Uni

Questions fréquentes

What is Frontotemporal Dementia (FTD)?

FTD is a type of dementia that mainly affects the parts of the brain controlling personality, behavior, language, and movement.

What does 'progranulin mutation' mean?

It means there's a specific change in a gene called progranulin, which is linked to your FTD.

What are 'Phase 1/2' studies?

These are early-stage studies to see if a new medicine is safe, well-tolerated, and to find the right dose. Phase 1 focuses on safety, and Phase 2 looks at effectiveness.

Will I get a placebo (dummy treatment)?

No, this is an 'open-label' study, which means everyone who joins will receive the study medicine, LY3884963.

Comment le médicament est-il administré ?

The medicine, LY3884963, will be given directly into the fluid around your brain and spinal cord through a procedure called intra-cisternal administration.

Comment en savoir plus

Parlez toujours à votre médecin généraliste ou spécialiste avant de décider de participer à une étude.

Discussion

Discussion communautaire

Propulsé par notre forum à community.patient.info. Veuillez être respectueux — ceci n'est pas un avis médical.